Isabela Valdés-Calero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Isabela Valdés-Calero has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Gema Frühbeck
Metabolic Research laboratory, Clínica Universidad de Navarra, Pamplona, Spain
2 shared publications - Adrián Gil-Korilis
Department of Endocrinology and Nutrition, Institute of Nutrition and Health, Clínica Universidad de Navarra, Pamplona, Spain
1 shared publication Allan Argueta
Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain
1 shared publication- Amaia Rodríguez
Metabolic Research laboratory, Clínica Universidad de Navarra, Pamplona, Spain
1 shared publication - Camilo Silva
CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III, Pamplona, Spain
1 shared publication - Carolina María Perdomo
Department of Endocrinology and Nutrition, Institute of Nutrition and Health, Clínica Universidad de Navarra, Pamplona, Spain; IdiSNA (Instituto de Investigación en la Salud de Navarra), Pamplona, Spain; CIBERObn (CIBER Fisiopatología de la Obesidad y Nutrición), Instituto de Salud Carlos III, Madrid, Spain
1 shared publication
Latest Publications
- Open Access
- 12 June 2026
- Published by Springer Nature in Current Obesity Reports
- Vol. 15 (1)
The Ghrelin-LEAP2 System in Obesity and Diabetes: Pathophysiological Roles and Therapeutic Potential
Purposeof Review: Ghrelin is a gut-derived acylated hormone that regulates appetite, food reward-related behaviours, glycaemic control, and lipid metabolism. These actions are primarily mediated through activation of the growth hormone secretagogue receptor (GHSR), which is highly expressed in the brain and also present in key metabolic organs. Ghrelin acylation by ghrelin O -acyltransferase (GOAT) is required for receptor binding and biological activity. This review examines the physiological and pathophysiological roles of ghrelin and liver-expressed antimicrobial peptide 2 (LEAP2), with particular emphasis on its relevance to obesity and type 2 diabetes. Recent Findings: LEAP2 has recently been identified as an endogenous antagonist and inverse agonist of GHSR that counteracts ghrelin signalling. Emerging evidence indicates that obesity and type 2 diabetes are generally associated with reduced circulating ghrelin levels and increased LEAP2 concentrations, particularly in the presence of insulin resistance. These reciprocal changes support the concept that the ghrelin/LEAP2 ratio functions as a dynamic regulator of energy balance, glucose homeostasis, and appetite control, and may influence metabolic responses to nutritional status and weight loss. Summary: The ghrelin-LEAP2 system represents a key regulatory pathway in metabolic homeostasis and a promising therapeutic target for obesity and related metabolic disorders. Pharmacological strategies targeting this axis, including ghrelin antagonists, LEAP2 analogues, GOAT inhibitors, and GHSR inverse agonists, are under active investigation, although further studies are required to establish their long-term efficacy and safety.
- 12 June 2026
- Published by Springer Nature in Current Obesity Reports
- Vol. 15 (1)
Open AccessThe Ghrelin-LEAP2 System in Obesity and Diabetes: Pathophysiological Roles and Therapeutic Potential
Purposeof Review: Ghrelin is a gut-derived acylated hormone that regulates appetite, food reward-related behaviours, glycaemic control, and lipid metabolism. These actions are primarily mediated through activation of the growth hormone secretagogue receptor (GHSR), which is highly expressed in the brain and also present in key metabolic organs. Ghrelin acylation by ghrelin O -acyltransferase (GOAT) is required for receptor binding and biological activity. This review examines the physiological and pathophysiological roles of ghrelin and liver-expressed antimicrobial peptide 2 (LEAP2), with particular emphasis on its relevance to obesity and type 2 diabetes. Recent Findings: LEAP2 has recently been identified as an endogenous antagonist and inverse agonist of GHSR that counteracts ghrelin signalling. Emerging evidence indicates that obesity and type 2 diabetes are generally associated with reduced circulating ghrelin levels and increased LEAP2 concentrations, particularly in the presence of insulin resistance. These reciprocal changes support the concept that the ghrelin/LEAP2 ratio functions as a dynamic regulator of energy balance, glucose homeostasis, and appetite control, and may influence metabolic responses to nutritional status and weight loss. Summary: The ghrelin-LEAP2 system represents a key regulatory pathway in metabolic homeostasis and a promising therapeutic target for obesity and related metabolic disorders. Pharmacological strategies targeting this axis, including ghrelin antagonists, LEAP2 analogues, GOAT inhibitors, and GHSR inverse agonists, are under active investigation, although further studies are required to establish their long-term efficacy and safety.
- Open Access
- 23 March 2026
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 40 (5) , 109314
Ultrasound assessment of abdominal fat: Subcutaneous maximum thickness as a practical marker of metabolic risk in primary care
- 23 March 2026
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 40 (5) , 109314
Open AccessUltrasound assessment of abdominal fat: Subcutaneous maximum thickness as a practical marker of metabolic risk in primary care
- Open Access
- 25 November 2025
- Published by Springer Nature in Hormones
- Vol. 25 (1) , 267-271
A synergistic drug combination that aids our battle against anaplastic thyroid carcinoma: a case report and discussion
Background: Anaplastic thyroid carcinoma (ATC) is a rare and highly aggressive malignancy historically associated with a poor prognosis and a median survival of only 3.16 months. However, recent advances in molecular profiling and immunotherapy are improving outcomes. Case presentation: We report the case of a 68-year-old man diagnosed with stage IVC ATC who achieved sustained disease stabilisation and long-term survival. Initial treatment with chemotherapy and radiotherapy led to partial remission of the primary tumour, although there was progression of metastatic disease. The patient was subsequently enrolled in a clinical trial investigating an anti-PD-L1 antibody with positive test results, followed by treatment with pembrolizumab. The latter resulted in nearly 11 years of disease control without significant adverse effects, an exceptional outcome in the context of ATC. Conclusion: This case underscores the transformative potential of immunotherapy in the management of advanced ATC and highlights the importance of continued research into combinatorial therapeutic strategies and predictive biomarkers to optimise treatment outcomes.
- 25 November 2025
- Published by Springer Nature in Hormones
- Vol. 25 (1) , 267-271
Open AccessA synergistic drug combination that aids our battle against anaplastic thyroid carcinoma: a case report and discussion
Background: Anaplastic thyroid carcinoma (ATC) is a rare and highly aggressive malignancy historically associated with a poor prognosis and a median survival of only 3.16 months. However, recent advances in molecular profiling and immunotherapy are improving outcomes. Case presentation: We report the case of a 68-year-old man diagnosed with stage IVC ATC who achieved sustained disease stabilisation and long-term survival. Initial treatment with chemotherapy and radiotherapy led to partial remission of the primary tumour, although there was progression of metastatic disease. The patient was subsequently enrolled in a clinical trial investigating an anti-PD-L1 antibody with positive test results, followed by treatment with pembrolizumab. The latter resulted in nearly 11 years of disease control without significant adverse effects, an exceptional outcome in the context of ATC. Conclusion: This case underscores the transformative potential of immunotherapy in the management of advanced ATC and highlights the importance of continued research into combinatorial therapeutic strategies and predictive biomarkers to optimise treatment outcomes.